ABVC Biopharma Inc
ABVC3.170USD
+0.420+15.27%
시장 운영 시간 （ET）시세는 15분 지연됩니다
48.75M시가총액
손실P/E TTM
자세한 내용은 ABVC Biopharma Inc 회사
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.
회사 정보
종목 코드 ABVC
회사 이름ABVC Biopharma Inc
상장일Nov 09, 2004
CEODr. Uttam Yashwant Patil
직원 수16
유형Ordinary Share
회계 연도 종료Nov 09
주소44370 Old Warm Springs Blvd
도시FREMONT
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호94538-6148
전화15106680881
웹사이트https://abvcpharma.com/
종목 코드 ABVC
상장일Nov 09, 2004
CEODr. Uttam Yashwant Patil
회사 임원
이름
이름/직위
직위
주식 보유
변동
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
1.00M
+3.82%
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
-11.15%
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
131.16K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Dr. Chang-Jen Jiang, M.D.
Dr. Chang-Jen Jiang, M.D.
Director
Director
42.03K
-0.12%
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
Ms. Yen-Hsin Chou
Ms. Yen-Hsin Chou
Independent Director
Independent Director
41.96K
--
Ms. Norimi Sakamoto
Ms. Norimi Sakamoto
Independent Director
Independent Director
41.85K
--
Ms. Hsin-Hui Miao
Ms. Hsin-Hui Miao
Independent Director
Independent Director
41.51K
-13.66%
Mr. Yu- Min (Francis) Chung
Mr. Yu- Min (Francis) Chung
Independent Director
Independent Director
41.39K
-1.33%
더 보기
이름
이름/직위
직위
주식 보유
변동
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
1.00M
+3.82%
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
-11.15%
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
131.16K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Dr. Chang-Jen Jiang, M.D.
Dr. Chang-Jen Jiang, M.D.
Director
Director
42.03K
-0.12%
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, May 17
마지막 업데이트: Sat, May 17
주주
주주 유형
주주
주주
비율
Jiang (Shuling)
5.98%
YuanGene, Corp
4.95%
Jiang (Tsung-Shann)
2.24%
Jiang (Eugene)
0.78%
Geode Capital Management, L.L.C.
0.62%
Other
85.43%
주주
주주
비율
Jiang (Shuling)
5.98%
YuanGene, Corp
4.95%
Jiang (Tsung-Shann)
2.24%
Jiang (Eugene)
0.78%
Geode Capital Management, L.L.C.
0.62%
Other
85.43%
주주 유형
주주
비율
Individual Investor
11.52%
Corporation
4.95%
Investment Advisor
1.02%
Investment Advisor/Hedge Fund
0.81%
Venture Capital
0.36%
Hedge Fund
0.08%
Other
81.25%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
34
3.14M
18.75%
-459.62K
2025Q1
36
3.18M
25.48%
-443.49K
2024Q4
37
3.35M
25.84%
-140.63K
2024Q3
38
3.28M
25.33%
-177.84K
2024Q2
39
3.21M
27.30%
-361.06K
2024Q1
37
3.25M
30.84%
+1.04M
2023Q4
37
1.92M
24.18%
+3.24K
2023Q3
39
1.80M
52.80%
+194.05K
2023Q2
37
1.48M
44.76%
-133.59K
2023Q1
36
1.48M
44.98%
+2.69K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Jiang (Shuling)
1.00M
5.98%
+36.89K
+3.82%
Apr 28, 2025
YuanGene, Corp
829.70K
4.95%
--
--
May 27, 2025
Jiang (Tsung-Shann)
375.99K
2.24%
-47.17K
-11.15%
Apr 28, 2025
Jiang (Eugene)
131.16K
0.78%
--
--
May 27, 2025
Geode Capital Management, L.L.C.
104.48K
0.62%
+25.20K
+31.78%
Mar 31, 2025
The Lind Partners, LLC
94.99K
0.57%
-105.06K
-52.52%
Dec 31, 2024
Patil (Uttam)
72.43K
0.43%
--
--
Apr 28, 2025
XTX Markets LLC
60.44K
0.36%
+26.03K
+75.67%
Mar 31, 2025
Odaira (Yoshinobu)
57.76K
0.34%
--
--
Apr 28, 2025
The Vanguard Group, Inc.
46.95K
0.28%
--
--
Mar 31, 2025
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
날짜
유형
비율
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
